GlassScriptPhysician profile
Shannon Kearney
NPI 1306843149
$47,807.11
in general payments reported to CMS, 2019-2025
51 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $1,415 · 2021: $2,149 · 2022: $4,116 · 2023: $14K · 2024: $10K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $16K · Travel and Lodging: $1,677 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,775.00 |
| Food and Beverage | $16,109.84 |
| Travel and Lodging | $1,677.11 |
| Education | $366.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28,744.41 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $3,350.98 | 2019-2025 | |
| Csl Behring | $2,842.00 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Glaxosmithkline, LLC. | $2,480.34 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,589.12 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $1,384.45 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $953.28 | 2021-2025 | Orladeyo |
| Amgen INC. | $942.69 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $783.46 | 2021-2025 | Ruconest, Joenja |
| Pfizer INC. | $685.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.25 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Blueprint Medicines Corporation | $446.45 | 2022-2025 | Ayvakit |
| Genentech USA, INC. | $346.24 | 2019-2025 | Xolair |
| Optinose US, INC. | $335.34 | 2019-2025 | |
| Grifols USA, LLC | $259.84 | 2019-2025 | Xembify |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $240.85 | 2023-2025 | Dupixent |
| Ionis Pharmaceuticals, INC. | $202.72 | 2025 | Dawnzera |
| Neurent Medical Limited | $142.30 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark System |
| Kaleo, INC. | $132.87 | 2020-2024 | Auvi-Q |
| Octapharma USA, INC. | $130.49 | 2021-2024 | Cutaquig |
| Aerin Medical INC. | $122.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.07 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $101.94 | 2022-2025 | |
| Inspire Medical Systems, INC. | $78.82 | 2023 | Inspire |
| Organogenesis INC. | $72.94 | 2023 | Puraply |
| Incyte Corporation | $67.53 | 2021-2025 | Opzelura |
| Alk-Abello, INC | $58.25 | 2022-2023 | Ragwitek, Odactra, Grastek |
| Aimmune Therapeutics, INC. | $55.90 | 2021-2022 | |
| Verona Pharma, INC. | $55.08 | 2025 | Ohtuvayre |
| Bio Products Laboratory USA, INC. | $44.94 | 2022-2023 | Gammaplex, Coagadex |
| Acclarent, INC | $38.26 | 2022 | |
| Biofire Diagnostics, LLC | $35.84 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $33.01 | 2025 | Neffy |
| Aytu Biopharma, INC. | $32.68 | 2021-2022 | |
| Mylan Specialty L.P. | $30.82 | 2024 | Yupelri |
| Leo Pharma INC. | $30.25 | 2022 | |
| Paratek Pharmaceuticals, INC. | $29.78 | 2025 | Xhance |
| Covis Pharma Gmbh | $28.22 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $26.60 | 2020-2021 | |
| Intersect Ent, INC. | $26.59 | 2022 | |
| X4 Pharmaceuticals, INC. | $24.77 | 2025 | Xolremdi |
| Abbvie INC. | $23.81 | 2022 | |
| Galderma Laboratories, L.P. | $23.24 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $22.96 | 2025 | Ryaltris |
| Stryker Corporation | $22.61 | 2019 | |
| Cycle Pharmaceuticals INC | $21.47 | 2025 | Sajazir |
| Phadia US INC. | $19.48 | 2023 | Immunocap |
| Cook Medical LLC | $19.04 | 2019 | |
| Horizon Therapeutics Plc | $14.61 | 2022 | |
| Lilly USA, LLC | $13.82 | 2024 | Ebglyss |
| Organon LLC | $8.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Kearney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.